Research and Markets - Global $30.2 Billion Respiratory Complications Therapeutics Market to 2022: Pfizer is Expected to Maintain its Position as Market Leader
DUBLIN, Apr. 07, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market" report to their offering.
"Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market" provides an introduction to the respiratory complications therapeutics market, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and prognosis.
In spite of a small late-stage pipeline, the respiratory complications market is forecast to grow moderately over the forecast period, from a value of $21.8 Billion in 2015 to $30.2 Billion in 2022, at a compound annual growth rate (CAGR) of 4.7%.
This growth will be predominantly driven by already marketed products, rather than the approval of pipeline products, which are expected to have a limited impact on the market. Furthermore, generic impact on the market will be limited in terms of value, given the very low cost of generics typically used.
There are few drugs that generate substantial revenue in the current respiratory complications market, with only one generating over $1 Billion from revenues specific to these complications. This is the Prevnar family pneumococcal disease vaccine, which has been approved for a broad spectrum of patients, ranging from six-week-old infants to adults of 50 and over. In 2015 the vaccine family generated $6.3 Billion, and this level of revenue is expected to remain relatively stable over the forecast period.
Pfizer is expected to maintain its position as market leader throughout the entire forecast period. Although the company has a large number of drugs active in this area, spread across pneumonia and pulmonary embolism, it is predominantly the pneumonia vaccine Prevnar that drives its revenue derived from respiratory complications. Pfizer is expected to generate $7.3 Billion by 2022, rising from $6.9 Billion in 2015 at a CAGR of 0.8%. This marginal growth is attributed to the limited revenue growth of Prevnar, as well as some revenue growth for the anticoagulant Eliquis (apixaban), which is expected to generate $642.8m from respiratory complications by 2022.
Key Topics Covered:
1 Introduction
2 Therapy Area Introduction
2.1 Symptoms
2.2 Diagnosis
2.3 Etiology and Pathophysiology
2.4 Epidemiology
2.5 Comorbidities and Complications
2.6 Prognosis
2.7 Treatment
2.7.1 Antibiotics
2.7.2 Antiviral Drugs
2.7.3 Vaccines
2.7.4 Antihypertensive drugs
2.7.5 Anticoagulants
2.7.6 Non-Pharmacological Treatments
3 Marketed Products
3.1 Overview
3.2 Prevnar 13 - Pfizer
3.3 Synflorix - GlaxoSmithKline
3.4 Uptravi - Actelion
3.5 Opsumit - Actelion
3.6 Eliquis - Bristol-Myers Squibb and Pfizer
3.7 Xarelto - Bayer
3.8 Synagis - Medimmune
3.9 Ventolin - GlaxoSmithKline
3.10 Infanrix and Boostrix - GlaxoSmithKline
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Solithera - Cempra
4.5.2 Carbavance (meropenem and vaborbactam) -The Medicines Company
4.5.3 Respiratory Syncytial Virus Vaccine - Novavax
4.5.4 Conclusion
5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target and Drug Category
5.3.1 Vaccines
5.3.2 G-Protein Coupled Receptors
5.3.3 Enzyme Targets
5.3.4 Bacterial and Viral Targets
5.4 Revenue and Market Share Analysis by Company
5.4.1 Pfizer - Prevnar Dominates Respiratory Complications Revenue
5.4.2 Actelion - Rapid Growth of PAH Therapies to Create a Strong Market Position
5.4.3 GSK - Vast Product Portfolio Will Help Maintain a Strong Market Position
5.4.4 Bayer - Despite Limited Portfolio, Xarelto Performance Sufficient to Establish Strong Market Position
5.4.5 Bristol-Myers Squibb - Growing Eliquis Revenue to Improve Respiratory Complications Market Position
5.4.6 Novavax - Approval of RSV Vaccine Will Help Establish Market Presence
5.4.7 United Therapeutics - Variant Treprostinil Formulation to Form Cornerstone of Market Presence
6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Value and Year
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Value and Year
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type and Value
7.2.4 Co-development Deals Valued Above $100m
8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase of Development
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-filed
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.2.8 Unknown
8.3 Abbreviations
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape
Companies Mentioned
- Actelion
- Bayer
- Bristol-Myers Squibb
- GlaxoSmithKline
- Medimmune
- Pfizer
For more information about this report visit http://www.researchandmarkets.com/research/3v8bdd/global
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article